Zepbound vs Mounjaro: All Tirzepatide Products

Mounjaro and Zepbound are both brand names for tirzepatide, manufactured by Eli Lilly. Like semaglutide's split between Ozempic and Wegovy, tirzepatide is marketed under two different names for two different conditions. Understanding these products and how compounded tirzepatide fits in can save you over $1,000 per month while accessing the same active ingredient.

Side-by-Side Comparison

Mounjaro: The Diabetes Product

Mounjaro was approved by the FDA in May 2022 as the first tirzepatide product for type 2 diabetes. As a dual GIP/GLP-1 receptor agonist, it represented a new class of medication that targets two incretin pathways simultaneously. Clinical trials showed Mounjaro produced A1C reductions of up to 2.3% and weight loss of up to 25 pounds at the highest doses in diabetes patients.

Before Zepbound's approval, Mounjaro was widely prescribed off-label for weight loss, similar to how Ozempic was used before Wegovy. Insurance coverage for Mounjaro is relatively strong for patients with type 2 diabetes but is typically denied when prescribed for weight loss alone.

Zepbound: The Weight Loss Product

Zepbound was approved in November 2023 specifically for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. The SURMOUNT clinical trials demonstrated remarkable results: patients on the highest dose (15 mg) lost an average of 22.5% of body weight over 72 weeks.

Zepbound's weight loss data exceeded what semaglutide (Wegovy) showed in comparable trials, making tirzepatide the most effective FDA-approved weight loss medication currently available. The 22.5% average weight loss at the highest dose compares favorably to Wegovy's 14.9%.

Same Drug, Different Labels

Mounjaro and Zepbound contain identical tirzepatide at identical doses. The only differences are the FDA-approved indication printed on the label and the insurance coverage pathway. Pharmacologically, they are interchangeable. Both come in the same dose options: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly injections.

Tirzepatide works through a dual mechanism:

• GLP-1 receptor activation: Reduces appetite, slows gastric emptying, and improves insulin sensitivity
• GIP receptor activation: Enhances the GLP-1 effects, improves fat metabolism, and may offer additional metabolic benefits

This dual mechanism is why tirzepatide produces greater weight loss than semaglutide (GLP-1 only) in clinical trials.

The Cost Problem

At approximately $1,000-1,200 per month retail, both Mounjaro and Zepbound are unaffordable for most patients without insurance coverage. And insurance coverage for weight loss medications remains inconsistent, with many plans excluding Zepbound entirely. Even Mounjaro coverage for diabetes often requires prior authorization and step therapy requirements.

This pricing gap is why compounded tirzepatide has become so popular. Through Trimi, compounded tirzepatide is available at $125/month, roughly one-tenth the cost of brand-name options. The active ingredient is the same tirzepatide molecule, prepared by FDA-registered 503B compounding pharmacies.

Compounded Tirzepatide: The Affordable Alternative

Compounded tirzepatide through Trimi at $125/month provides:

• Same active ingredient as Mounjaro and Zepbound
• Flexible dosing customized by your provider
• No insurance pre-authorization required
• Flat-rate pricing that does not increase with higher doses
• Consistent availability without brand-name supply shortages
• Medications from FDA-registered 503B compounding pharmacies

Dosing and Titration

Both brand-name products follow the same titration schedule:

• Weeks 1-4: 2.5 mg/week (starting dose)
• Weeks 5-8: 5 mg/week
• Weeks 9-12: 7.5 mg/week
• Weeks 13-16: 10 mg/week
• Weeks 17-20: 12.5 mg/week
• Week 21+: 15 mg/week (maximum dose)

With compounded tirzepatide through Trimi, providers can customize this titration based on individual tolerance and response, potentially adjusting more slowly or stopping at a lower maintenance dose if patients achieve their goals without needing the maximum dose.

Side Effects

Side effects are identical across Mounjaro, Zepbound, and compounded tirzepatide because the active ingredient is the same. The most common include nausea (most frequent during titration), diarrhea, constipation, decreased appetite, vomiting, injection site reactions, and abdominal pain. Most side effects are mild to moderate and improve over time as your body adjusts.

How to Choose

• If you have type 2 diabetes with insurance coverage: Mounjaro may be covered with a reasonable copay
• If your insurance covers Zepbound for weight loss: Brand-name Zepbound is an excellent option
• If cost is a concern or insurance does not cover tirzepatide: Compounded tirzepatide through Trimi at $125/month provides the same medication at a fraction of the cost
• If you want to compare tirzepatide with semaglutide: Trimi offers both compounded semaglutide ($125/month) and compounded tirzepatide ($125/month)

Getting Started

If you are interested in tirzepatide for weight loss, visit Trimi's treatment options page. Compounded tirzepatide starts at $125/month with provider consultations, medication, and shipping included. Our providers can help determine whether semaglutide or tirzepatide is the better fit for your goals.

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Yes, both contain identical tirzepatide. Mounjaro is approved for type 2 diabetes and Zepbound for weight loss, but the medication itself is the same molecule at the same doses.

Is tirzepatide better than semaglutide for weight loss?

Clinical trials show tirzepatide produces greater average weight loss than semaglutide (22.5% vs 14.9% at maximum doses). However, individual responses vary, and some patients do better on semaglutide. Trimi offers both so providers can match you with the optimal medication.

Why is compounded tirzepatide so much cheaper?

Brand-name tirzepatide pricing reflects Eli Lilly's development costs and market positioning. Compounded tirzepatide from 503B pharmacies eliminates brand premiums. Through Trimi, compounded tirzepatide is $125/month compared to $1,000+ for brand-name options.

Can I switch from Mounjaro to compounded tirzepatide?

Yes. Switching from brand-name to compounded tirzepatide is straightforward since it is the same active ingredient. A Trimi provider will match your current dose and continue your treatment seamlessly.